Molnupiravir

Molnupiravir is a nucleoside analogue that inhibits SARS-CoV-2 replication by viral mutagenesis for the treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19) who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 therapy approved or authorized by FDA are not available/accessible or clinically appropriate.

Note: Molnupiravir is not FDA-approved for any use including for use for the treatment of COVID-19. The FDA has granted an emergency use authorization (EUA) for the treatment of coronavirus disease (COVID-19).

Limitations of Authorized Use:

• Molnupiravir is not recommended/authorized for use in those who are less than 18 years of age.
  
• It is not authorized for initiation of treatment in those hospitalized due to COVID-19. The benefit of treatment with Molnupiravir has not been observed in subjects when treatment was initiated after hospitalization due to COVID-19.
  
• Molnupiravir is not recommended/authorized for use for longer than five-consecutive days.
  
• It is not authorized for pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

The recommended dosage for adult patients is 800 mg (four 200 mg capsules) orally every 12 hours for 5 days, with or without food. Initiate treatment as promptly as possible following a diagnosis of COVID-19 has been made, and within 5 days of sign and symptom onset. Completion of the full five-day treatment course and continued isolation as per the public health recommendations are crucial to maximize viral clearance and mitigate the transmission of SARS-CoV-2.

In case a patient misses a dose of Molnupiravir capsules within 10 hours of the time it is typically taken, the patient needs to take it as quickly as possible and resume the standard dosing schedule. In case the patient misses a dose by more than 10 hours, the patient need not take the missed dose and instead take the very next dose at the scheduled time. The patient must not double the dose to make up for a missed dose.

• Hypersensitivity reactions, including anaphylaxis, may occur with Molnupiravir. In case signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, promptly stop treatment and initiate appropriate medicines and/or supportive care.
  
• Molnupiravir is not recommended for use in those aged less than 18 years because it may affect bone and cartilage growth. Bone and cartilage toxicity was noted in rats after repeated dosing. The safety and efficacy of Molnupiravir therapy have not been established in pediatric patients.
  
• The use of Molnupiravir capsules is not authorized during pregnancy. Women of childbearing age or potential should use appropriate contraception for the duration of treatment and for 4 days after the final dose of molnupiravir.
  
• Breastfeeding is not recommended throughout treatment and for 4 days after the final dose of molnupiravir. A lactating individual may consider interrupting breastfeeding and may consider pumping and discarding breast milk throughout treatment and for 4 days after the final dose of molnupiravir.

What documents are required to import Molnupiravir to India?

Molnupiravir capsules can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)
  

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

Molnupiravir is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

• IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
  
• On availability of Molnupiravir in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of Molnupiravir (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Molnupiravir 200 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the Molnupiravir (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

Is Molnupiravir FDA approved?

FDA has issued an emergency use authorization (EUA) for the emergency use of the unapproved medicinal product molnupiravir. EUA is not the same as FDA approval or licensure.

What is the dosage and form of Molnupiravir® supplied?

Molnupiravir® is supplied as Capsules: 200 mg for oral administration. 

What is the dose and duration of Molnupiravir? 

Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours, with or without food, for five days. This is 8 capsules per day. Molnupiravir is not authorized for use for longer than five consecutive days and needs to be started within 5 days of sign and symptom onset. 

What are the most common side effects of Molnupiravir®? 

The most common side effects of Molnupiravir® are nausea, dizziness, and diarrhea. 

How much does Molnupiravir cost in India?

The cost of Molnupiravir in India can vary. To procure this nucleoside analogue legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Molnupiravir®?

Store capsules at 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Is it safe to buy Molnupiravir® online in India?

Yes, one can buy Molnupiravir online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can facilitate the supply of Molnupiravir capsules through legal channels.